false 0001574094 0001574094 2024-01-02 2024-01-02 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

 

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported): January 2, 2024 (December 26, 2023)

 

RenovoRx, Inc.

(Exact name of registrant as specified in its charter)

 

Delaware   001-40738   27-1448452

(State or other Jurisdiction

of Incorporation)

  

(Commission

File Number)

  

(IRS Employer

Identification No.)

 

4546 El Camino Real, Suite B1

Los Altos, CA 94022

(650) 284-4433

 

(Address and telephone number, including area code, of registrant’s principal executive offices)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
   
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
   
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
   
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act: None.

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company ☒

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

 

 
 

 

Item 8.01. Other Events

 

RenovoRx, Inc. (the “Company”) reports with great sadness the passing of David Diamond on December 26, 2023. Mr. Diamond served the Company with distinction since May 2021 as a member of the Company’s Board of Directors (the “Board”) and will be greatly missed. Mr. Diamond served as Chair of the Audit Committee of the Board, as a member of the Compensation Committee of the Board and as the Lead Independent Director. In due course, the Board will seek a replacement for Mr. Diamond.

 

The Company extends its deepest sympathies to the Diamond family.

 

 
 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

  RenovoRx, Inc.
     
Date: January 2, 2024 By: /s/ Shaun Bagai
  Name: Shaun R. Bagai
  Title: Chief Executive Officer

 

 

 

v3.23.4
Cover
Jan. 02, 2024
Cover [Abstract]  
Document Type 8-K
Amendment Flag false
Document Period End Date Jan. 02, 2024
Entity File Number 001-40738
Entity Registrant Name RenovoRx, Inc.
Entity Central Index Key 0001574094
Entity Tax Identification Number 27-1448452
Entity Incorporation, State or Country Code DE
Entity Address, Address Line One 4546 El Camino Real
Entity Address, Address Line Two Suite B1
Entity Address, City or Town Los Altos
Entity Address, State or Province CA
Entity Address, Postal Zip Code 94022
City Area Code (650)
Local Phone Number 284-4433
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Entity Emerging Growth Company true
Elected Not To Use the Extended Transition Period false
RenovoRx (NASDAQ:RNXT)
Historical Stock Chart
From May 2024 to Jun 2024 Click Here for more RenovoRx Charts.
RenovoRx (NASDAQ:RNXT)
Historical Stock Chart
From Jun 2023 to Jun 2024 Click Here for more RenovoRx Charts.